Association of Molecular Pathology Annual Meeting 2015

Austin Convention Center

November 5-7

Booth #1229

To address the existing bottlenecks of using NGS in translational research, we’ve created a line of innovative products that are purpose-built for clinical oncology research.

By combining revolutionary Anchored Multiplex PCR (AMP™) chemistry with an easy-to-use workflow and intuitive software, we are unleashing the power of translational NGS to enable accurate and scalable mutation detection.

Archer™ NGS assays are purpose-built for clinical research

Robust platform to enrich targeted RNA or DNA

Detect known and unknown regions by NGS

Scalable cost- and labor-effective workflow

Comprehensive time-saving automated sequence analysis


Archer FusionPlex: The New Standard in NGS-based Gene Fusion Detection

Presented by Dr. Maria Arcila

Gene fusions are important therapeutic targets in oncology, but traditional detection methodologies fall short of the throughput requirements needed in today's molecular labs. ArcherDX has combined innovative enrichment chemistry and analysis algorithms to create a purpose-built NGS-based fusion detection assay. The assay workflow is simple and scalable, and analysis is accessed through an intuitive, web-based interface.

FusionPlex assays can simultaneously identify fusion transcripts, splicing variants, point mutations, and transcript abundance from FFPE sections of solid tumors, sarcomas, and hematological malignancies. In this workshop, we will present data that demonstrates the utility and distinct advantages of the Archer FusionPlex system.

Dr. Arcila is an anatomic and clinical pathologist at the Memorial Sloan Kettering Cancer Center, where she specializes in molecular genetic pathology and hematology. As a molecular genetic pathologist, Dr. Arcila's work primarily involves the study and detection of genetic changes in cancer tissue, which can be used to diagnose individual cancer types.

Dr. Arcila's research is focused on the molecular changes that fuel the development of lung carcinoma and the search for possible therapeutic and prognostic markers in patients with the disease. Due to this interest, Dr. Arcila has become involved with the expansion of clinical tests at MSK to detect mutations relevant to the management and treatment of patients with lung carcinoma.

Anchored Multiplex PCR: A Quantitative, Targeted Approach for Tumor Profiling by NGS

Presented by Dr. John Iafrate

Detection of point mutations, base insertions or deletions (indels), and copy number variants (CNVs) were historically accomplished using multiple testing technologies, yielding high costs and long turn-around times. Despite the promise of NGS, existing target enrichment technologies do not preserve the molecular diversity needed to support robust calling of somatic mutations.

Anchored Multiplex PCR (AMP) is a purpose-built, target enrichment chemistry for NGS that enables fusion transcript, point mutation, indel, and CNV detection from a single FFPE sample. In this workshop, ArcherDX describes consolidating quantitative analysis of point mutations, indels, and CNVs into a single NGS-based assay with VariantPlex assays.

Dr. Iafrate is a board-certified pathologist at Massachusetts General Hospital. He oversees the Center for Integrated Diagnostics, which provides rapid personalized genomic testing to help inform cancer treatment decisions for patients. Prior to working for Massachusetts General Hospital and Harvard University, Dr. Iafrate received his MD and PhD from State University of New York at Stony Brook and subsequently trained at Brigham and Women's Hospital for Anatomic and Molecular Genetic Pathology.

Posters featuring ArcherDX technology

H18. Detection of dual IDH1 and IDH2 mutations by targeted next-generation sequencing in acute myeloid leukemia and myelodysplatic syndromes

M. Platt, A.T. Fathi, D.R. Borger, A.M. Brunner, R.P. Hasserjian, L. Balaj, A. Lum, S. Yip, D. Dias-Santagata, Z. Zheng, L.P. Le, T.A. Graubert, A.J. Iafrate, V. Nardi

Massachusetts General Hospital, Boston, MA; University of British Columbia, Vancouver, BC, Canada

H53. Detection of chromosome translocations associated with myeloid malignancies using targeted RNA next-generation sequencing panel

T.M. Schneider, G. Smith, C. Hill, L. Zhang

Emory University, Atlanta, GA

ST31. Detection of gene fusions in sarcomas by Anchored Multiplex PCR for targeted next-generation sequencing

N.V. Guseva, A.A. Stence, R. Sompallae, J.C. Schade, A.D. Bossler, D. Ma

University of Iowa Hospitals and Clinics, Iowa City, IA

ST33. Different variants of NAB2-STAT6 gene fusion in solitary fibrous tumor detected by a next-generation sequencing-based assay and clinical pathologic correlations

N.V. Guseva, A.A. Stance, R. Sompallae, J.C. Schade, M.R. Tanas, A.D. Bossler, A.M. Belizzi, D. Ma

University of Iowa Hospitals and Clinics, Iowa City, IA

ST73. Analytical validation of an NGS-based diagnostic test to detect common fusions in solid tumors from formalin-fixed, paraffin-embedded (FFPE) tissues

M. Telatar, M.T. Cuellar, C. Louie, M. Afkhami, R. Pillai, D. Gu, P. Chu, P, Auon

City of Hope National Medical Center, Duartea, CA

ST75. Development and validation of an RNA seq assay for the detection of gene fusions in tumors

A.M. McDonald, B. Kipp, J.Jen, W.E. Highsmith, K. Rumilla, S. Kerr, U. Aypar, R. Jenkins, W. Sukov, C. Botz, R. Graham, J. Voss, B. Crusan, X. Wang

Mayo Clinic, Rochester, MN

ST99. Archer targeted sequencing technology for the detection of oncogenic fusion transcripts in solid tumors: A validation study

R. Benayed, C. O'Reilly, G. Jour, M. Hameed, L. Wang, M.F. Berger, M.E. Arcila, M. Ladanyi

Memorial Sloan Kettering Cancer Center, New York, NY

ST103. Clinical utility of the ArcherDX FusionPlex Sarcoma Panel in the formalin-fixed tissues: A proof of principle study

T. Schneider, M. Clay, G. Smith, C. Hill

Emory University, Atlanta, GA

ST104. Evaluation of the Archer FusionPlex Solid Tumor Panel in the JAX cancer traetment profile

S. Helm, T. Mitchell, A. Ras, V. Spotlow, K. Kelly, S. Mockus, C. Statz, G. Ananda, J. Malcolm, G.J. Tsongalis

The Jackson Laboratory for Genomic Medicine, Farmington, CT; Dartmouth Hitchcock Medical Center and The Audrey and Theodor Geisel School of Medicine at Dartmouth, Lebanon, NH

ST106. Identification of fusion genes in sarcoma patients using the Archer FusionPlex Sarcoma Panel

F.B. de Abreu, J. Peterson, K.B. Linos, J.B. Pettus, A. LaBonte, C. Mealmaker, A. Teator, T. Bowers, G. Tsongalis

Dartmouth-Hitchcock Medical Center and The Audrey and Theodor Geisel School of Medicine at Dartmouth, Lebanon, NH; Dartmouth-Hitchcock Medical Center, Lebanon, NH; ArcherDX, Boulder, CO; ArcherDX, Coulter, CO

ST123. Targeted detection of copy number variants and fusion transcripts greatly expands the ability to detect oncogenic drivers in NSCLC

L. Johnson, J. Covino, N. Manoj, M. Bessette, E. Baravik, A. Licon, R. Walters, B. Culver, J. Stahl, J. Haimes, B. Kudlow

ArcherDX Inc., Boulder, CO

Click here for AMP 2015 Meeting Resources

How to contact us


2477 55th Street, Suite 202

Boulder, CO 80301


Phone: (877) 771 1093

Phone: (303) 357 9001

All content © 2018 ArcherDX, Inc.

For Research Use Only. Not for use in diagnostic procedures. For Research Use Only. Not for use in diagnostic procedures.